Eli Lilly and Company (LLY)

 

For the full year of 2009, we expect earnings per share to be in the range of $4.00 to $4.25. We expect volume growth in sales again in 2009, driven by Cymbalta, Alimta, Cialis, Humalog, and the anticipated launches of prasugrel, as well as by the Elanco animal health division. However, the negative impact of weaker foreign currencies, worldwide pricing pressures, and the impact of generic competition in certain markets for Gemzar are anticipated to partially offset these positive impacts. As a result, we expect mid-single digit sales growth. We expect gross margin as a percent of net sales to increase, driven by the strengthening dollar. This increase could be more pronounced in the first half of 2009. Marketing, selling, and administrative expenses are expected to show flat to low-single digit growth. Research and development expenses are projected to grow in the low-double digits. Other — net is expected to be a net loss of between $200 million and $250 million. Capital expenditures are expected to be approximately $1.1 billion, and we expect continued strong operating cash flow.

 

Actual results could differ materially and will depend on, among other things, the continuing growth of our currently marketed products; developments with competitive products; the timing and scope of regulatory approvals and the success of our new product launches; asset impairments, restructurings, and acquisitions of compounds under development resulting in acquired in-process research and development charges; foreign exchange rates and global macroeconomic conditions; changes in effective tax rates; wholesaler inventory changes; other regulatory developments, litigation, and government investigations; and the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals. We undertake no duty to update these forward-looking statements.

 

 

For the full year of 2009, we expect earnings per share to be in
the range of $4.00 to $4.25. We expect volume growth in sales
again in 2009, driven by Cymbalta, Alimta, Cialis, Humalog, and
the anticipated launches of prasugrel, as well as by the Elanco
animal health division. However, the negative impact of weaker
foreign currencies, worldwide pricing pressures, and the impact
of generic competition in certain markets for Gemzar are
anticipated to partially offset these positive impacts. As a
result, we expect mid-single digit sales growth. We expect gross
margin as a percent of net sales to increase, driven by the
strengthening dollar. This increase could be more pronounced in
the first half of 2009. Marketing, selling, and administrative
expenses are expected to show flat to low-single digit growth.
Research and development expenses are projected to grow in the
low-double digits. Other — net is expected to be a net
loss of between $200 million and $250 million. Capital
expenditures are expected to be approximately $1.1 billion,
and we expect continued strong operating cash flow.

 

Actual results could differ materially and will depend on, among
other things, the continuing growth of our currently marketed
products; developments with competitive products; the timing and
scope of regulatory approvals and the success of our new product
launches; asset impairments, restructurings, and acquisitions of
compounds under development resulting in acquired in-process
research and development charges; foreign exchange rates and
global macroeconomic conditions; changes in effective tax rates;
wholesaler inventory changes; other regulatory developments,
litigation, and government investigations; and the impact of
governmental actions regarding pricing, importation, and
reimbursement for pharmaceuticals. We undertake no duty to
update these forward-looking statements.